Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Eso, Yuji, Takeda, Haruhiko, Taura, Kojiro, Takai, Atsushi, Takahashi, Ken, Seno, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534657/
https://www.ncbi.nlm.nih.gov/pubmed/34677270
http://dx.doi.org/10.3390/curroncol28050352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534657/
https://www.ncbi.nlm.nih.gov/pubmed/34677270
http://dx.doi.org/10.3390/curroncol28050352

Ejemplares similares